NVS
NovartisCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Execution beats on core portfolio and successful launches/approvals push revenue and margin upside; cost discipline and share buybacks support multiple expansion toward the analyst high (~$175) as investors re-rate growth optionality.
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.6.
What can break
Accelerated biosimilar/generic erosion in key markets
Momentum
49
Value
65
Sentiment
50
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $144.40 · Bull $175.00 · Bear $109.51
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-04 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $151.88
Why
Momentum49 · Δ7d -0.6
Value65 · Δ7d +0.6
Sentiment50 · Δ7d +7.3
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
49
34% active weight
Current posture
7d trendSoftening
Δ7d
-0.6
Δ21d
+24.5
Value
65
32% active weight
Current posture
7d trendFlat
Δ7d
+0.6
Δ21d
+0.7
Sentiment
50
33% active weight
Current posture
7d trendImproving
Δ7d
+7.3
Δ21d
+7.5
Why this grade
Composite grade C. Momentum 48.7 / Value 65.1 / Sentiment 49.9
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$262.16B
Beta
0.78
Shares Out
1.92B
P/E (TTM)
18.7
P/S (TTM)
5.16
P/FCF (TTM)
31.31
Rev YoY
+9.0%
EPS YoY
+28.7%
Gross Margin
+76.1%
Op Margin
+31.0%
Net Debt
$17.91B
Current Ratio
0.88
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology